Tada, 

Just to clarify, I was suggesting that they could hit 50% RRR not exceed it (though I wouldn't complain). So you and I aren't too far off. You suggested an upper limit of 45%, I suggested 50%. But honestly, anywhere in the 25% to 50% range would be amazing. Of course, these RRR numbers are an average of three individual RRR  components: cardiovascular death, heart attack and stroke. It could be that similar to Jardiance/Empagliflozin that the 3-point MACE RRR is dominated by one strong individual component (cardiovascular death was significantly reduced by 38% in EMPA-REG Outcomes, but differences in heart attack and stroke were not significant). 

On total side note, I had a thought cross my mind earlier today. What is the standard of care treatment for glucose control for the diabetes related symptoms in BETonMACE patients? With the SGLT2 inhibitors Jardiance/Empagliflozin and Invokana/Canagliflozin, as well as the GLP1 receptor agonist Victoza/Liraglutide all being diabetes drugs showing significantly reduced 3-point MACE in clinical trials that have read out since the start of BETonMACE...... 1) How many patients in BETonMACE are on these diabetes drug mentioned above or were these drugs not allowed as a diabetes standard of care for BETonMACE eligibility? 2) If allowed, how much of an impact will these drugs have on the overall MACE event rate in BETonMACE? 3) Will apabetalone have a blunted MACE lowering effect in those patients on these drugs, or will the MACE lowering effects be additive? 4) If there are a large number of patients on these drugs, this may provide post hoc analysis opportunity to suggest that apabetalone has an additional MACE lowering effect in patients treated with SGLT2 inhibitors or GLP1 receptor agonists.

BearDownAZ